Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | PDE5A | O76074 | 17/20 | 0.79 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.79 |
| ▸ | PDE6C | P51160 | 3/20 | 0.79 |
| ▸ | PDE2A | O00408 | 2/20 | 0.79 |
| ▸ | PDE9A | O76083 | 2/20 | 0.79 |
| ▸ | PDE4A | P27815 | 2/20 | 0.79 |
| ▸ | PDE1A | P54750 | 2/20 | 0.79 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.79 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.79 |
| ▸ | PDE6D | O43924 | 1/20 | 0.79 |
| ▸ | PDE8A | O60658 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | HTR1A | P08908 | 1/20 | 0.79 |
| ▸ | PDE6A | P16499 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628860 | 0.92 | KMT2A (0.85) | KMT2AKDM4EPDE5APDE3BPDE3A | |
| SCHEMBL1071 | 0.91 | KMT2A (0.83) | KMT2AKDM4EPDE5APDE3BPDE3A | |
| SCHEMBL29655374 | 0.91 | KMT2A (0.83) | KMT2AKDM4EPDE5APDE3BPDE3A | |
| SCHEMBL30848678 | 0.90 | PDE5A (0.95) | KMT2AKDM4EPDE5APDE3BPDE3A | |
| SCHEMBL28890961 | 0.90 | KMT2A (0.71) | KMT2AKDM4EPDE5APDE3BPDE3A | |
| SCHEMBL24430033 | 0.89 | PDE5A (0.89) | KMT2AKDM4EPDE5APDE3BPDE3A | |
| Sildenafil SCHEMBL34463415 | 0.89 | PDE5A (0.94) | PDE5APDE3BPDE3APDE6CPDE2A | |
| Sildenafil SCHEMBL2112660 | 0.89 | PDE5A (0.94) | PDE5APDE3BPDE3APDE6CPDE2A | |
| Sildenafil SCHEMBL1895 | 0.88 | PDE5A (1.00) | KMT2APDE5APDE3BPDE3APDE6C | |
| Sildenafil SCHEMBL5683880 | 0.88 | PDE5A (1.00) | KMT2APDE5APDE3BPDE3APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-119367314-A | Aidinafil sustained-release pellet and preparation method and application thereof | 北京悦康科创医药科技股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166157-B | Double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-115837013-B | Aidenafil citrate capsule and preparation method and application thereof | 北京悦康科创医药科技股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-116270553-B | Aidinafil oral film-dissolving agent and preparation method thereof | 北京悦康科创医药科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-116270553-A | Aidinafil oral film-dissolving agent and preparation method thereof | 北京悦康科创医药科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115969781-A | Aidenafil citrate injection and preparation method and application thereof | 北京悦康科创医药科技股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115837013-A | Aidenafil citrate capsule and preparation method and application thereof | 北京悦康科创医药科技股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20220193081-A1 | LIQUID SILDENAFIL CITRATE COMPOSITIONS | ELLAMED IP & SERVICES PTE. LTD. (SG) | 2022-06-23 | — | — | US | disclosed |
| EP-3956024-A1 | LIQUID SILDENAFIL CITRATE COMPOSITIONS | Ellamed IP & Services Pte. Ltd. (SG) | 2022-02-23 | — | — | EP | disclosed |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3887376-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166157-A | Novel double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-112645954-A | Sildenafil raw material medicine impurity, preparation method thereof and application of sildenafil raw material medicine impurity as reference substance | 植恩生物技术股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020109354-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020109354-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE9A, PDE5A, PDE2A | KMT2A 3573/4885KDM4E 2159/4885PDE5A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.